Codiak BioSciences collaborates with Ragon Institute to evaluate exoVACC vaccine platform in SARS-CoV-2 and HIV
Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes Covid-19, and in (2) human immunodeficiency virus (HIV).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.